10/06/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/6/2020. The Food and Drug Administration (FDA) has issued this 18-page guidance to provide sponsors of requests for Emergency Use Authorization (EUA) for COVID-19 vaccines with recommendations regarding the data and information needed to support the issuance of an EUA for an investigational vaccine to prevent COVID-19 for the duration of the COVID-19 public health emergency. (PDF)
10/06/2020 12:00 AM EDT
Source: Centers for Medicare & Medicaid Services (CMS). Published: 10/6/2020. The Centers for Medicare & Medicaid Services (CMS) has released new regulatory requirements in this 12-page memorandum for all hospitals and critical access hospitals to report COVID-19 data elements in accordance with a frequency and in a standardized format as specified by the Secretary during the public health emergency for COVID-19. (PDF)
10/06/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 10/6/2020. This 20-page document aims to provide guidance to healthcare facilities and healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) on preparedness and infection prevention and control (IPC) measures for the management of possible and confirmed cases of COVID-19 in healthcare settings, including long-term care facilities (LTCFs). It also addresses the management of clinical diagnostic specimens at laboratories in the EU/EEA. (PDF)
10/06/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the ZEUS ELISA SARS-CoV-2 IgG Test System. The ZEUS ELISA SARS-CoV-2 IgG Test System is authorized for the detection of antibodies to SARS-CoV-2 in human serum and plasma (dipotassium EDTA, lithium heparin and sodium citrate). (PDF)
10/06/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the UCLA SwabSeq COVID-19 Diagnostic Platform. The UCLA SwabSeq COVID19 Diagnostic Platform is authorized for use with upper respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
10/05/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 10/5/2020. The principal mode by which people are infected with SARS-CoV-2 (the virus that causes COVID-19) is through exposure to respiratory droplets carrying infectious virus. This web page details potential airborne transmission of respiratory viruses, and how SARs-CoV-2 is spread. (Text)
10/05/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/5/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the AQ-TOP COVID-19 Rapid Detection Kit PLUS. The AQ-TOP COVID-19 Rapid Detection Kit PLUS is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
10/02/2020 12:00 AM EDT
Source: Occupational Safety and Health Administration [U.S. Department of Labor] (OSHA). Published: 10/2/2020. This web page details temporary guidance for enforcing initial and annual fit-testing requirements related to tight-fitting powered air-purifying respirators. The new enforcement discretion policy permits the use of National Institute for Occupational Safety and Health (NIOSH)-approved tight-fitting powered air-purifying respirators for protection against the coronavirus when initial and/or annual fit testing is infeasible due to respirator and fit-testing supply shortages. The guidance applies to healthcare personnel and other workers in high or very high exposure risk activities. (Text)
10/01/2020 12:00 AM EDT
Source: National Bureau of Economic Research (NBER). Published: 10/2020. This 68-page report estimates the impact of mask mandates and other non-pharmaceutical interventions (NPI) on COVID-19 case growth in Canada, including regulations on businesses and gatherings, school closures, travel and self-isolation, and long-term care homes. Counterfactual policy simulations suggest that mandating indoor masks nationwide in early July could have reduced the weekly number of new cases in Canada by 25 to 40 percent in mid-August, which translates into 700 to 1,100 fewer cases per week. (PDF)
10/01/2020 12:00 AM EDT
Source: American College of Obstetricians and Gynecologists (ACOG). Published: 10/2020. This web page provides links to COVID-19 FAQs for obstetrician-gynecologists. FAQ topics are Ethics, Telehealth, Obstetrics, and Gynecology. (Text)
10/01/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 10/2020. Across the WHO European Region, Member States are reporting signs of pandemic fatigue in their populations – defined as demotivation to follow recommended protective behaviors, emerging gradually over time and affected by a number of emotions, experiences, and perceptions. This 28-page framework document provides key considerations for the planning and implementation of national and subnational strategies to maintain and reinvigorate public support to prevent COVID-19. (PDF)
10/01/2020 12:00 AM EDT
Source: International Federation of Red Cross and Red Crescent Societies (IFRC). Published: 10/2020. This 24-page joint report, sponsored by the International Committee of the Red Cross (ICRC), International Federation of Red Cross and Red Crescent Societies (IFRC), Danish Red Cross, Lebanese Red Cross, and Swedish Red Cross, collates seven case studies from mental health and psychosocial support (MHPSS) activities around the world to highlight how Red Cross and Red Crescent volunteers are treating the hidden wounds of the COVID-19 pandemic among the world’s most vulnerable communities. (PDF)
09/30/2020 12:00 AM EDT
Source: U.S. House of Representatives, Committee on Appropriations. Published: 9/30/2020. Witnesses at this one-hour, 18-minute Congressional hearing discuss how agencies have implemented the appropriate COVID-19 response funding for the Indian Health Service, and tribal and urban Indian health organizations; the new and continuing challenges in addressing the pandemic; and how the federal government can help tribal nations, Indian health facilities, and Bureau of Indian Education-funded schools. (Video or Multimedia)
09/24/2020 12:00 AM EDT
Source: Congressional Research Service [Library of Congress] (CRS). Published: 9/24/2020. This 47-page report discusses how data privacy and security (together, data protection) law applies to a public health authority’s use of digital contact tracing tools, the role of technology in assisting with contact tracing, and potential privacy concerns. Appendix A provides Digital Contact Tracing Apps By State. (PDF)
09/16/2020 12:00 AM EDT
Source: Congressional Research Service [Library of Congress] (CRS). Published: 9/16/2020. This three-page report details the data from an annual government survey of U.S. manufacturers, analyzed in conjunction with official U.S. trade statistics, that provides some insight into domestic medical supply production activities, including personal protective equipment and pharmaceuticals, and a rough estimate of the share that some imported medical products make up in total U.S. supply. (PDF)
09/01/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 9/2020. This seven-page document details how it will be critical in the upcoming influenza season to implement comprehensive measures that ensure best possible protection against influenza among risk groups that are also at high risk of severe COVID-19 disease, including hospitalization and death; decrease number of persons requiring medical care as a result of influenza infection to limit pressures on health services; and reduce the potential for SARS-CoV-2 exposure while seeking treatment for influenza or being admitted to hospital for influenza. (PDF)
.png)
No hay comentarios:
Publicar un comentario